The EAF2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from HeLa cells, engineered to disrupt the EAF2 gene. This loss-of-function model enables the investigation of EAF2??s role in transcriptional elongation and tumor biology without introducing clonal selection biases. The polyclonal format preserves a heterogeneous mixture of edited alleles, providing a robust system for functional genomics studies.
HeLa cells, isolated from a human cervical adenocarcinoma, are an epithelial cell line widely employed in cancer research and studies of HPV-related oncogenesis. Their well-characterized transcriptional landscape and transformed phenotype make them an ideal host for dissecting the contributions of elongation factors like EAF2 to malignancy. The cervical origin also provides a relevant context for examining how transcriptional dysregulation intersects with viral oncoproteins.
EAF2 is a component of the super elongation complex (SEC), where it directly interacts with ELL, AF4, ENL, AF9, and P-TEFb (CDK9/Cyclin T1) to facilitate transcriptional elongation by RNA Polymerase II. It functions downstream of androgen receptor signaling and MLL fusion proteins, and its activity promotes the expression of genes such as MYC and BCL2, thereby influencing cell proliferation and apoptosis. Through these interactions, EAF2 integrates upstream oncogenic signals to modulate transcriptional output.
Disruption of EAF2 in HeLa cells is predicted to impair SEC-mediated elongation, leading to altered expression of key target genes and potential defects in cell cycle regulation and survival. This model is particularly valuable for exploring the tumor-suppressive roles of EAF2 in cervical adenocarcinoma and for understanding how HPV-driven transformation might exploit transcriptional elongation pathways.
Researchers can use these knockout cells to study transcription elongation mechanisms by performing RNA-seq to assess global transcriptomic changes, co-immunoprecipitation to examine SEC complex assembly, and western blotting or RT-qPCR to quantify downstream targets. Additional applications include functional characterization of tumor suppressors, drug target validation for transcription-related cancers, and phenotypic assays for proliferation and apoptosis. For inquiries, please contact Ascent Research.
